MX2015008187A - Inhibidores de alk deuterados. - Google Patents
Inhibidores de alk deuterados.Info
- Publication number
- MX2015008187A MX2015008187A MX2015008187A MX2015008187A MX2015008187A MX 2015008187 A MX2015008187 A MX 2015008187A MX 2015008187 A MX2015008187 A MX 2015008187A MX 2015008187 A MX2015008187 A MX 2015008187A MX 2015008187 A MX2015008187 A MX 2015008187A
- Authority
- MX
- Mexico
- Prior art keywords
- alk inhibitors
- deuterated
- compositions
- inhibitors
- compound
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a inhibidores de ALK novedosos de Fórmula I: como se define en la especificación, así como sales farmacéuticamente aceptables de los mismos. La invención también proporciona composiciones que comprenden un compuesto de esta invención y el uso de dichas composiciones en métodos para tratar enfermedades y condiciones que son benéficamente tratadas mediante la administración de inhibidores de ALK.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739892P | 2012-12-20 | 2012-12-20 | |
| US201361750646P | 2013-01-09 | 2013-01-09 | |
| US201361769886P | 2013-02-27 | 2013-02-27 | |
| PCT/US2013/076607 WO2014100431A1 (en) | 2012-12-20 | 2013-12-19 | Deuterated alk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015008187A true MX2015008187A (es) | 2016-02-05 |
Family
ID=50002837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008187A MX2015008187A (es) | 2012-12-20 | 2013-12-19 | Inhibidores de alk deuterados. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150299166A1 (es) |
| EP (1) | EP2935251A1 (es) |
| JP (1) | JP2016503798A (es) |
| AU (1) | AU2013361320A1 (es) |
| CA (1) | CA2895846A1 (es) |
| MX (1) | MX2015008187A (es) |
| WO (1) | WO2014100431A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015188073A1 (en) | 2014-06-06 | 2015-12-10 | Research Triangle Institute | Apelin receptor (apj) agonists and uses thereof |
| CN108350006B (zh) * | 2015-11-27 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 氘修饰的Brigatinib衍生物、含有该化合物的药物组合物及其用途 |
| CN106188138B (zh) * | 2015-12-02 | 2018-07-24 | 深圳市塔吉瑞生物医药有限公司 | 一种二氨基嘧啶化合物及包含该化合物的组合物 |
| BR112018011784A2 (pt) | 2015-12-09 | 2018-12-04 | Res Triangle Inst | agonistas aprimorados do receptor de apelina (apj) e usos dos mesmos |
| CN105777710B (zh) * | 2016-04-05 | 2018-09-04 | 湖南欧亚药业有限公司 | 一种艾乐替尼的合成方法 |
| ES2875329T3 (es) | 2016-09-16 | 2021-11-10 | Res Triangle Inst | Antagonistas de opioides kappa de tetrahidroisoquinolina |
| CN114507217A (zh) | 2016-10-12 | 2022-05-17 | 三角研究所 | 杂环爱帕琳肽受体(apj)激动剂及其用途 |
| WO2018119076A1 (en) | 2016-12-21 | 2018-06-28 | Research Triangle Institute | Diaryl purine derivatives with improved bioavailability |
| JP2021534202A (ja) | 2018-08-20 | 2021-12-09 | デューク ユニバーシティ | 眼科疾患を処置する為の薬物の為の方法及び組成物 |
| CN114008242B (zh) * | 2019-06-21 | 2024-12-13 | 朗姆研究公司 | 双向转位装置 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| EP1390063B1 (en) | 2001-05-03 | 2004-11-17 | F. Hoffmann-La Roche Ag | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| WO2006039237A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| EP2190841B1 (en) | 2007-08-14 | 2013-05-15 | Concert Pharmaceuticals Inc. | Substituted oxazolidinone derivatives |
| ES2402748T3 (es) | 2007-12-11 | 2013-05-08 | Theravance, Inc. | Compuestos de aminotetralina como antagonistas del receptor de opioide mu |
| WO2009154754A2 (en) | 2008-06-17 | 2009-12-23 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| DK3345903T3 (da) | 2009-06-10 | 2019-11-11 | Chugai Pharmaceutical Co Ltd | Tetracykliske forbindelser |
| WO2012119006A2 (en) | 2011-03-03 | 2012-09-07 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
-
2013
- 2013-12-19 US US14/653,745 patent/US20150299166A1/en not_active Abandoned
- 2013-12-19 JP JP2015549719A patent/JP2016503798A/ja active Pending
- 2013-12-19 WO PCT/US2013/076607 patent/WO2014100431A1/en not_active Ceased
- 2013-12-19 MX MX2015008187A patent/MX2015008187A/es unknown
- 2013-12-19 AU AU2013361320A patent/AU2013361320A1/en not_active Abandoned
- 2013-12-19 EP EP13824429.8A patent/EP2935251A1/en not_active Withdrawn
- 2013-12-19 CA CA2895846A patent/CA2895846A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014100431A1 (en) | 2014-06-26 |
| EP2935251A1 (en) | 2015-10-28 |
| US20150299166A1 (en) | 2015-10-22 |
| JP2016503798A (ja) | 2016-02-08 |
| CA2895846A1 (en) | 2014-06-26 |
| AU2013361320A1 (en) | 2015-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015008187A (es) | Inhibidores de alk deuterados. | |
| MY178621A (en) | Deuterated cftr potentiators | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| IN2014KN02601A (es) | ||
| IN2015DN01156A (es) | ||
| MD4666B1 (ro) | Inhibitori ai Syk | |
| NZ715747A (en) | Syk inhibitors | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| IN2014MN02598A (es) | ||
| NZ726366A (en) | Syk inhibitors | |
| MX2016002794A (es) | Compuestos antiproliferativos. | |
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| IN2015DN01119A (es) | ||
| MX2015012741A (es) | Palbociclib deuterado. | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| PH12017500595B1 (en) | Aldosterone synthase inhibitors | |
| MD4780B1 (ro) | Urei asimetrice p-substituite şi utilizările medicale ale acestora | |
| EA201491878A1 (ru) | Замещенные ксантиновые производные | |
| MX2014001862A (es) | 5-cicloalquil-o 5-heterociclil-nicotinamidas. | |
| WO2012119006A3 (en) | Derivatives of pyrazole-substituted amino-heteroaryl compounds | |
| PH12012501476A1 (en) | Aminoquinoline derivatives | |
| NZ629475A (en) | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines |